Metformin continuation post‐metabolic bariatric surgery and relapse of diabetes
Authors' conclusion
Among individuals living with obesity and diabetes who achieved diabetes remission post-MBS, metformin continuation was not associated with relapse of diabetes. This lack of an association indicates that metformin did not provide an additional benefit for maintaining glycaemic control or weight reduction during an average of 5 years postsurgery.
Study context
- Population
- Clalit Health Service members aged ≥24 years with obesity and diabetes treated with metformin, who underwent metabolic bariatric surgery (MBS) 2005–2020 and achieved HbA1c <6.5% up to 6 months after surgerymatched 1:2
- Participants
- 122 vs 244
- Exposure
- Metformin continuation vs stopping after MBS
- Continued metforminn = 122
- Stopped metforminn = 244reference
- Outcome
- Relapse of diabetes (HbA1c ≥6.5%)
Methodological detailsobservational, matched (1:2) on age, sex and HbA1c at index date
- Observational
- Matched (1:2) on age, sex and HbA1c at index date
Main finding
As reported in the abstract
No significant association of metformin continuation after MBS with relapse of diabetes
aHR 1.70 (0.98-2.94) (95% CI)
Observational data: associations, not effects.
Further findings
Weight loss and filled prescriptions for other diabetes medications · follow-up
- No significant differences between the two groups
Mean HbA1c during follow-up · mean ≈5 years
- Both matched groups maintained mean HbA1c <6.5%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →